Eton Pharmaceuticals Inc. (ETON)
14.37
-0.48 (-3.23%)
At close: Feb 20, 2025, 3:59 PM
14.39
0.17%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 13.77 |
| Market Cap | 382.61M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.21 |
| PE Ratio (ttm) | -68.4 |
| Forward PE | n/a |
| Analyst | Strong Buy |
| Ask | 15.4 |
| Volume | 348,863 |
| Avg. Volume (20D) | 281,640 |
| Open | 14.37 |
| Previous Close | 14.85 |
| Day's Range | 14.18 - 15.09 |
| 52-Week Range | 3.03 - 18.41 |
| Beta | undefined |
About ETON
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezip...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 13, 2018
Employees 30
Stock Exchange NASDAQ
Ticker Symbol ETON
Website https://www.etonpharma.com
Analyst Forecast
According to 3 analyst ratings, the average rating for ETON stock is "Strong Buy." The 12-month stock price forecast is $21, which is an increase of 46.19% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Eton Pharmaceuticals Inc. is scheduled to release its earnings on Mar 13, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
+10.78%
Eton Pharmaceuticals shares are trading higher aft...
Unlock content with
Pro Subscription
3 months ago
+15.59%
Eton Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results. HC Wainwright & Co. reiterated a Buy rating on the stock.
